Investors :: ProMIS Neurosciences, Inc. (PMN)

Latest News

November 14, 2024

ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights

View Press Release View All News

November 12, 2024

ProMIS Neurosciences to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference

October 30, 2024

ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer’s Disease Conference

September 12, 2024

ProMIS Neurosciences to Showcase PMN310’s Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences

Latest Presentation

August 8, 2024

Corporate Overview

View Presentation View All Presentations

Recent Event

November 13, 2024 10:00 am EST

Guggenheim’s Inaugural Healthcare Innovation Conference

View Event View All Events

Latest Financial Results

Q3 2024

Quarter Ended Sep 30, 2024

Earnings Release

10-Q

PDF HTML

XBRL

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2023

Company Overview

ProMIS™ Neurosciences, Inc. (Nasdaq: PMN), is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). The Company has offices in Toronto, Ontario, and Cambridge, Massachusetts.

View Management Team View Board of Directors

Toronto, Canada Office

Address

1920 Yonge Street
Suite 200
Toronto, ON M4S 3E2
Canada

Cambridge, MA U.S. Office

Address

Cambridge Innovation Center
1 Broadway
Cambridge, MA 02142
U.S.A.